Trial results

A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range

NCT06041217 on ClinicalTrials.gov · last registry update 2026-05-18

Finished 2 April 2025, after enrolling 242 people. Primary outcome, as filed: Change in Body Weight (%). semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status

COMPLETED

Phase

P3

Drug

semaglutide

Wegovy, Ozempic, Rybelsus

Sponsor

Novo Nordisk A/S

Sponsor type

Industry

Enrollment

242

Started

2023-09-15

Primary completion

2025-04-02 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Body Weight (%)

Conditions studied

Overweight · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.